|
1
|
Socinski MA, Okamoto I, Hon JK, Hirsh V,
Dakhil SR, Page RD, Orsini J, Yamamoto N, Zhang H and Renschler MF:
Safety and efficacy analysis by histology of weekly nab-paclitaxel
in combination with carboplatin as first-line therapy in patients
with advanced non-small-cell lung cancer. Ann Oncol. 24:2390–2396.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Crvenkova S and Pesevska M: Important
prognostic factors for the long-term survival in non-small cell
lung cancer patients treated with combination of chemotherapy and
conformal radiotherapy. J BUON. 20:775–781. 2015.PubMed/NCBI
|
|
3
|
Lin Q, Liu Y, Wang N, Huang Y, Ge X, Ren
X, Chen X, Hu J, Guo Z, Zhao Y and Asaumi J: A modified phase I
trial of radiation dose escalation in 3D conformal radiation
therapy with concurrent vinorelbine and carboplatin chemotherapy
for non-small-cell lung cancer. J Radiat Res. 54:126–134. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mubarak N, Gaafar R, Shehata S, Hashem T,
Abigeres D, Azim HA, El-Husseiny G, Al-Husaini H and Liu Z: A
randomized, phase 2 study comparing pemetrexed plus best supportive
care versus best supportive care as maintenance therapy after
first-line treatment with pemetrexed and cisplatin for advanced,
non-squamous, non-small cell lung cancer. BMC Cancer. 12:4232012.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fu L, Chen W, Guo W, Wang J, Tian Y, Shi
D, Zhang X, Qiu H, Xiao X, Kang T, et al: Berberine targets
AP-2/hTERT, NF-kappaB/COX-2, HIF-1alpha/VEGF and
Cytochrome-c/Caspase signaling to suppress human cancer cell
growth. PLoS One. 8:e692402013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cheong SM, Choi H, Hong BS, Gho YS and Han
JK: Dab2 is pivotal for endothelial cell migration by mediating
VEGF expression in cancer cells. Exp Cell Res. 318:550–557. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ma X, Jia Y, Zu S, Li R, Jia Y, Zhao Y,
Xiao D, Dang N and Wang Y: α5 Nicotinic acetylcholine receptor
mediates nicotine-induced HIF-1α and VEGF expression in non-small
cell lung cancer. Toxicol Appl Pharmacol. 278:172–179. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li G, He L, Zhang E, Shi J, Zhang Q, Le
AD, Zhou K and Tang X: Overexpression of human papillomavirus (HPV)
type 16 oncoproteins promotes angiogenesis via enhancing HIF-1α and
VEGF expression in non-small cell lung cancer cells. Cancer Lett.
311:160–170. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yu FS, Yu CS, Chen JC, Yang JL, Lu HF,
Chang SJ, Lin MW and Chung JG: Tetrandrine induces apoptosis Via
caspase-8, −9 and −3 and poly (ADP ribose) polymerase dependent
pathways and autophagy through beclin-1/ LC3-I, II signaling
pathways in human oral cancer HSC-3 cells. Environ Toxicol.
31:395–406. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chen Y, Chen JC and Tseng SH: Tetrandrine
suppresses tumor growth and angiogenesis of gliomas in rats. Int J
Cancer. 124:2260–2269. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tao LJ, Zhou XD, Shen CC, Liang CZ, Liu B,
Tao Y and Tao HM: Tetrandrine induces apoptosis and triggers a
caspase cascade in U2-OS and MG-63 cells through the intrinsic and
extrinsic pathways. Mol Med Rep. 9:345–349. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jimenez-Mateos EM, Arribas-Blazquez M,
Sanz-Rodriguez A, Concannon C, Olivos-Ore LA, Reschke CR, Mooney
CM, Mooney C, Lugara E, Morgan J, et al: microRNA targeting of the
P2X7 purinoceptor opposes a contralateral epileptogenic focus in
the hippocampus. Sci Rep. 5:174862015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bass MB, Yao B, Hei YJ, Ye Y, Davis GJ,
Davis MT, Kaesdorf BA, Chan SS and Patterson SD: Challenges in
developing a validated biomarker for angiogenesis inhibitors: The
motesanib experience. PLoS One. 9:e1080482014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Infante JR, Novello S, Ma WW, Dy GK,
Bendell JC, Huff A, Wang Q, Suttle AB, Allen R, Xu CF, et al: Phase
Ib trial of the oral angiogenesis inhibitor pazopanib administered
concurrently with pemetrexed in patients with advanced solid
tumors. Invest New Drugs. 31:927–936. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu J and Liu Y: Influence of erbanxiao
solution on inhibiting angiogenesis in stasis toxin stagnation of
non-small cell lung cancer. J Tradit Chin Med. 33:303–306. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hu X, Zhang J, Xu B, Jiang Z, Ragaz J,
Tong Z, Zhang Q, Wang X, Feng J, Pang D, et al: Multicenter phase
II study of apatinib, a novel VEGFR inhibitor in heavily pretreated
patients with metastatic triple-negative breast cancer. Int J
Cancer. 135:1961–1969. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Smith GA, Fearnley GW, Tomlinson DC,
Harrison MA and Ponnambalam S: The cellular response to vascular
endothelial growth factors requires co-ordinated signal
transduction, trafficking and proteolysis. Biosci Rep. 35:pii:
e00253. 2015. View Article : Google Scholar
|
|
18
|
Noonan S, Wong Man K and Jimeno A:
Nintedanib, a novel triple angiokinase inhibitor for the treatment
of non-small cell lung cancer. Drugs Today (Barc). 51:357–366.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lee JG and Wu R: Erlotinib-cisplatin
combination inhibits growth and angiogenesis through c-MYC and
HIF-1alpha in EGFR-mutated lung cancer in vitro and in vivo.
Neoplasia. 17:190–200. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pore N, Gupta AK, Cerniglia GJ, Jiang Z,
Bernhard EJ, Evans SM, Koch CJ, Hahn SM and Maity A: Nelfinavir
down-regulates hypoxia-inducible factor 1alpha and VEGF expression
and increases tumor oxygenation: Implications for radiotherapy.
Cancer Res. 66:9252–9259. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gogali A, Charalabopoulos K, Zampira I,
Konstantinidis AK, Tachmazoglou F, Daskalopoulos G, Constantopoulos
SH and Dalavanga Y: Soluble adhesion molecules E-cadherin,
intercellular adhesion molecule-1 and E-selectin as lung cancer
biomarkers. Chest. 138:1173–1179. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Thanopoulou E, Kotzamanis G, Pateras IS,
Ziras N, Papalambros A, Mariolis-Sapsakos T, Sigala F, Johnson E,
Kotsinas A, Scorilas A and Gorgoulis VG: The single nucleotide
polymorphism g.1548A >G (K469E) of the ICAM-1 gene is associated
with worse prognosis in non-small cell lung cancer. Tumour Biol.
33:1429–1436. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hayes SH and Seigel GM: Immunoreactivity
of ICAM-1 in human tumors, metastases and normal tissues. Int J
Clin Exp Pathol. 2:553–560. 2009.PubMed/NCBI
|
|
24
|
Hsu YC, Chiu YT, Cheng CC, Wu CF, Lin YL
and Huang YT: Antifibrotic effects of tetrandrine on hepatic
stellate cells and rats with liver fibrosis. J Gastroenterol
Hepatol. 22:99–111. 2007. View Article : Google Scholar : PubMed/NCBI
|
